Repligen (NASDAQ:RGEN) Rating Lowered to “Hold” at Zacks Research

Repligen (NASDAQ:RGEN) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday, Zacks reports.

A number of other research firms have also recently commented on RGEN. JPMorgan Chase & Co. upped their target price on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Citigroup raised shares of Repligen to a “buy” rating in a report on Tuesday, July 7th. HSBC cut their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Wells Fargo & Company lifted their target price on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Finally, Wolfe Research assumed coverage on shares of Repligen in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $168.57.

Repligen Price Performance

Repligen stock opened at $194.57 on Monday. The firm has a market cap of $10.98 billion, a PE ratio of 266.53, a price-to-earnings-growth ratio of 3.54 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The stock’s fifty day moving average price is $167.55 and its two-hundred day moving average price is $140.04. Repligen has a one year low of $100.99 and a one year high of $198.87.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. During the same period in the previous year, the firm earned $0.26 EPS. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, research analysts expect that Repligen will post 2.06 EPS for the current fiscal year.

Institutional Trading of Repligen

A number of large investors have recently bought and sold shares of RGEN. ABS Investment Management LLC bought a new stake in Repligen in the 2nd quarter worth about $191,016,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Repligen in the 2nd quarter worth about $52,000. Trust Co. of Vermont bought a new position in Repligen during the 2nd quarter worth approximately $71,000. Harbor Investment Advisory LLC lifted its holdings in Repligen by 198.9% in the 2nd quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company’s stock worth $71,000 after buying an additional 348 shares during the period. Finally, Allworth Financial LP bought a new stake in Repligen during the second quarter worth about $71,000. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.